Project Grant R21AI183544
Award Date
12/16/24
Completion Date
3/10/25
Dollars Obligated
$534K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This is a Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855). The grant aims to explore the impact of gender-affirming hormone therapy on HIV viral dynamics and immune responses in transgender women. The $2,314,470 award will fund research over a 5-year period from November 2024 to October 2029. The principal investigator is leveraging two cohorts of transgender women, including a...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $149,528 to The Johns Hopkins University to conduct research on the mechanisms underlying sex differences in vaccine-induced immunity. The research aims to investigate how estrogen receptor signaling and mTOR activation in B cells influence metabolic processes and contribute to greater antibody...
This $158,085 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund a mixed methods study to assess and promote vaginal health for transgender men on testosterone. The study aims to: 1) Develop a survey instrument to measure the vaginal health of transgender men on testosterone for clinical use; 2) Examine the psychometric properties of the survey items to finalize the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Grant Program (CFDA 93.855), provides $439,088 to The General Hospital Corporation (Massachusetts General Hospital) to mechanistically define how sex differences in hormones and circulating cytokines modulate B cell class switch recombination, a core immune reaction underlying humoral immunity. The research aims to rigorously elucidate a...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $440,700.00 to New York University School of Medicine to conduct research focused on improving HIV vaccine design. The key goals are to: 1) Design and validate an immunogen targeting the V2B neutralization epitope on the HIV/SIV viral spike, and 2) Test the combination of vaccine-elicited anti-V2B...
The federal Project Grant award R01AI187016 for $737,761.00, awarded on August 1, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance HIV prevention through a vaccine approach that promotes durable immunity. The key objectives are to induce robust CD4 T follicular helper (TFH) cells, which are essential for vigorous B cell activity within germinal centers, to facilitate the...
This $112,956 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at Texas A&M University System Health Science Center to study how biological sex impacts innate immune and metabolic responses that influence infection susceptibility. The award aims to leverage the Drosophila melanogaster genetic model to assess the impact of post-mating reproductive changes in females, but not males,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $745,752 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mayo Clinic. The funding supports research to develop an HIV-1 vaccine that can generate strong immune responses at mucosal surfaces, the primary sites of HIV exposure. Key aspects of the project include: Evaluating the ability of a "single-cycle" adenovirus (SC-AD) vaccine platform to amplify antigen production...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $814,873 to conduct research on the immunogenetics of the COVID-19 immune response. The key objectives are to: Perform a large genome-wide association study to identify genetic associations with COVID-19 infection and vaccine-induced immune responses, including antibody levels. This includes replicating findings in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $464,750 to the Icahn School of Medicine at Mount Sinai to investigate the mechanisms of mucosal immune responses induced by mRNA-based and Newcastle Disease Virus (NDV)-based COVID-19 vaccine platforms. The research aims to understand how these vaccine technologies can prime mucosal B cells and promote their recirculation to induce...